IRLAB’s annual report for 2020 is now available on the company’s website

April 15, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the annual report for 2020 is published on In addition, the company’s website has been visually updated.

IRLAB’s annual report for 2020 and other documents for the annual general meeting on May 6, 2021 are now available to download on the company’s website, An English-language version of the annual report will be published before the annual general meeting.

Digital Annual General Meeting

Due to the continued spread of Covid-19 and to ensure the safety of our shareholders, the annual general meeting will this year be held without physical presence, as previously announced. Participation at the annual general meeting will instead occur by using a digital postal voting form, available on in the menu ‘Corporate Governance’ or through the following link:

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                

Viktor Siewertz, CFO
Phone: +46 727 10 70 70


IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on